子宫颈鳞癌骨桥蛋白检测与放疗预后的关系

 目的 探讨子宫颈鳞癌骨桥蛋白（OPN）与放疗预后的关系。方法 用免疫组织化学SP法检测71例放疗失败（复发或未控）的子宫颈鳞癌患者和71例同期放疗治愈的子宫颈鳞癌患者放疗前病检标本OPN，并用酶联免疫吸附试验（ELISA）检测两组患者放疗后血浆的OPN含量。结果 Ⅱ期患者失败组标本的骨桥蛋白表达在放疗前后都明显高于治愈组（P＜0.01）；Ⅲ期患者两组标本放疗前OPN表达均高于Ⅱ期（P＜0.05），但Ⅲ期患者两组标本的骨桥蛋白表达放疗前后差异均无统计学意义（P＞0.05）；放疗失败组再次发病时血浆OPN为（231.1±53.4）ng／ml，明显高于治愈组治疗后的（167.6±41.7）ng／ml（P＜0.01）。结论 放疗前标本中的OPN表达可以预测子宫颈鳞癌放疗的预后；血浆OPN检测具有标本检测同样的临床意义；血浆OPN浓度的定量检测更方便实用，可以为诊断、疗效监测特别是动态监测治疗后复发和转移提供帮助。

Correlation between expressions of osteopontin in squamous carcinoma of cervix and the prognosis of radiotherapy

Objective To explore the relationship between the expressions of osteopontin (OPN) and postradiotherapy plasma level of osteopontin in squamous carcinoma of cervix and evaluate their significance. Methods A total of 71 patients receiving radiotherapy from January 1998 to January 2001 were enrolled in this study. The expression of OPN protein were evaluated by SP immunohistochemistry and the plasma levels of OPN were detected by ELISA. Results The levels of OPN were not significant different between the two groups in stageⅢ(P ＞0.05); but the levels of OPN in stageⅢ(84.0 % and 88.0 %) were significantly higher than those of stage Ⅱ(P ＜0.05); in stageⅡ the levels of OPN expression in failure group were 80.4 %, 76.1 % before and after radiotherapy, they were significantly higher than those in control group(P ＜0.01); the level of OPN in failure group after radiotherapy was(231.1±53.4) ng/ml. It was significantly higher than that in control group in stageⅢ(167. 6±41.7) ng/ml (P ＜0.01). Conclusion The expressions of osteopontin in preradiothera－py are in association with the prognosis of radiotherapy; The higher plasma levels of OPN after radiotherapy will mean radiotherapy failure.